

Remarks

Claims 1-23 were pending in the subject application. By this Amendment, claims 1, 13 and 15 have been amended, new claim 24 has been added and claims 22-23 have been canceled. Support for the amendments can be found, for example, at page 6, lines 10-16; page 12, lines 18-25; page 17; and page 25. Entry and consideration of the amendments presented herein is respectfully requested. Accordingly, claims 1-21 are currently before the Examiner for consideration. Applicant respectfully submits that these amendments will require no further search on the part of the Examiner and do not constitute new matter. Favorable consideration of the pending claims is respectfully requested.

It should also be understood that the amendments presented herein have been made solely to expedite prosecution of the subject application to completion. These amendments should not be construed as an indication of Applicant's agreement with or acquiescence to, the rejections of record. Applicant expressly reserves the right to pursue the invention(s) disclosed in the subject application, including any subject matter canceled or not pursued during prosecution of the subject application, in a related application. Favorable consideration of the claims now presented, in view of the remarks and amendments set forth herein, is earnestly solicited.


Claims 1-23 have been rejected under 35 U.S.C. §112, first paragraph, as failing to convey to one skilled in the art that the inventor had possession of the claimed invention. More particularly, the Office Action maintains that "the specification does not describe the use and effect of various human tissues' amino acid mixtures in the treatment of various damaged tissues." The Office Action goes on to state that the specification teaches only the use of Neocate, which has an amino acid formulation characteristic of human breast milk protein, for the treatment of Crohn's disease. Thus, the Office Action contends that the genus of "a plurality of enantiomerically pure L-amino acids and glycine" and the amounts thereof is unpredictable. Applicant respectfully disagrees with this basis of rejection, however, Applicant has amended the claim as suggested in the Office Action. Accordingly, it is respectfully submitted that this issue is now moot and reconsideration and withdrawal of the rejection is respectfully requested.

In view of the foregoing remarks and amendments to the claims, Applicant believes that the currently pending claims are in condition for allowance, and such action is respectfully requested.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16 or 1.17 as required by this paper to Deposit Account 19-0065.

Applicant invites the Examiner to call the undersigned if clarification is needed on any of this response, or if the Examiner believes a telephonic interview would expedite the prosecution of the subject application to completion.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: Saliwanchik, Lloyd & Saliwanchik
A Professional Association
P.O. Box 142950
Gainesville, FL 32614-2950

FCE/gld